Watson Pharmaceuticals
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Watson Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count).
Watson Pharmaceuticals: 28 sponsored US clinical trials, none currently recruiting.
Watson Pharmaceuticals sponsors 28 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 28 completed. 17 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Detrusor Hyperreflexia, with 2 trials.
Top-decile sponsor footprint
Watson Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
28 of 28 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
28 total, page 1 of 1
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
NCT02193139
Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
NCT01323140
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01161563
Study of Silodosin to Facilitate Passage of Urinary Stones
NCT01144949
Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception
NCT01140217
Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men
NCT01104246
Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
NCT00919113
Effects of Oxybutynin Topical Gel on Gastric Emptying
NCT00926926
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
NCT00793819
Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
NCT00740779
Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers
NCT00752141
Comparison Between Effects of Two Iron Preparations on Protein in the Urine
NCT00534144
Effect of Two Iron Preparations on Protein in the Urine
NCT00354692
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
NCT00350636
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
NCT00224133
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
NCT00224120
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
NCT00224107
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
NCT00224029
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
NCT00224016
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
NCT00224081
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
NCT00224146
2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.
NCT00223977
Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients
NCT00223964
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients
NCT00224055
Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients
NCT00224003
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents
NCT00224042
Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy
NCT00224068
A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women
NCT00224094
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 7 |
| Phase 3 | 5 |
| Phase 4 | 12 |
How the Watson Pharmaceuticals archive is shaped
28 indexed studies, none listed as recruiting (0% open); 28 completed (100%).
Phase mix: 17 late (III/IV) vs 11 early (I/II) (later-stage heavy).
Top condition: Detrusor Hyperreflexia (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Watson Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 28 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Watson Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 28 archived trials
- Axsome Therapeutics · 28 trials · 21% recruiting
- Benaroya Research Institute · 28 trials · 14% recruiting
- CAMC Health System · 28 trials · 11% recruiting
- CTI BioPharma · 28 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Watson Pharmaceuticals page
28 registered trials is a research-attention snapshot, not an endorsement of Watson Pharmaceuticals or any single study.
- None of Watson Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Detrusor Hyperreflexia is the condition Watson Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Detrusor Hyperreflexia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Watson Pharmaceuticals pipeline card: 28 registered trials from official public datasets.Report a data error.